scPharmaceuticals, Inc. Forecast, price target & analysts
scPharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
scPharmaceuticals, Inc. Classifications & Recommendation:
scPharmaceuticals, Inc. Price Target
| Target Price | $9.18 |
| Price | $5.67 |
| Potential |
61.90%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target scPharmaceuticals, Inc. 2026 .
The average scPharmaceuticals, Inc. target price is $9.18.
This is
61.90%
register free of charge
$26.25
362.96%
register free of charge
$5.40
4.70%
register free of charge
|
|
| A rating was issued by 10 analysts: 6 Analysts recommend scPharmaceuticals, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the scPharmaceuticals, Inc. stock has an average upside potential 2026 of
61.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 36.33 | 74.23 |
| 167.33% | 104.31% | |
| EBITDA Margin | -177.90% | -72.42% |
| 55.86% | 59.29% | |
| Net Margin | -234.38% | -79.58% |
| 41.89% | 66.05% |
6 Analysts have issued a sales forecast scPharmaceuticals, Inc. 2025 . The average scPharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an scPharmaceuticals, Inc. EBITDA forecast 2025. The average scPharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 scPharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average scPharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.91 | -1.11 |
| 34.51% | 41.88% | |
| P/E | negative | |
| EV/Sales | 4.24 |
6 Analysts have issued a scPharmaceuticals, Inc. forecast for earnings per share. The average scPharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
scPharmaceuticals, Inc....
Current scPharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Aug 26 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Aug 26 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
